Anticancer drug company: Medivation (MDVN)-delisting (2004)

Medivation, Inc. (NASDAQ:MDVN) was founded in December 2004 and is headquartered in San Francisco, California, with 485 full-time employees. It is a biotechnology medical company focusing on the treatment of intractable diseases, including: Treatment of prostate cancer, breast cancer and pancreatic cancer.

Updated : September 28, 2016, Pfizer (Pfizer Inc.) beat Sanofi , completed Maidi Wei’s Medical Medivation Inc. acquisition.

Medivation Inc Logo

Medivation (MDVN):

Medivation is an American biopharmaceutical company that focuses on the rapid development of new therapies to treat serious diseases with very limited current treatments. Medivation is currently working with Astellas (a Japanese company) to develop XTANDI® (enzalutamide), which can be used for the treatment of prostate cancer and breast cancer.

Enzalutamide is a novel, once-daily oral androgen receptor signaling inhibitor. The drug can inhibit multiple steps in the androgen receptor signaling pathway and is designed to interfere with the ability of testosterone to bind to prostate cancer cells. The drug has been shown to reduce the growth of cancer cells and induce tumor cell death.

  • As early as August 31, 2012, Medivation and Astellas have been approved by the U.S. Food and Drug Administration ( FDA ) to produce XTANDI® (enzalutamide) capsules for metastatic castration that has previously received polycetaxel therapy. Treatment of patients with sexual prostate cancer (mCRPC).
  • In addition, on March 18, 2014, Medivation and Astellas jointly announced that it had submitted a supplementary new drug application (sNDA) for the prostate cancer drug Xtandi (enzalutamide) to the FDA, seeking approval for Xtandi for use in patients who have not received chemotherapy. Treatment of male patients with metastatic castrated prostate cancer (mCRPC). At that time, Xtandi had been approved for the treatment of mCRPC patients who had previously received docetaxel chemotherapy.
  • On June 2, 2016, Medivation will determine which shareholders are eligible to issue a written application to replace its board of directors. After the company rejected the company’s merger proposal, the French pharmaceutical company Sanofi nominated 8 members to replace the entire company’s board of directors.
  • On August 22, 2016, Pfizer Pharmaceuticals reportedly approached a $14 billion acquisition of Medivation. The premium rate of the acquisition was about 30%. The successful acquisition by Pfizer also announced the acquisition of Medivation by Merck and Sanofi . The offer failed.

Medivation Medical (MDVN) investment:

After hitting a record low of $4.22 in August 2010, Madison Medical’s stock price has soared 26 times in 5 years, and the latest closing price is more than 100 US dollars. Even if the investment started at the end of October 2011, the current investment The return rate is still more than 13 times, which is a standard 10 times stock.

Compared with JUNO , ADRO , BLUE , BLCM, etc., Medivation is a mature anti-cancer drug company with products on the market, which deserves attention.

The latest ratings of Medivation Medical

Rating date

Rating company


Initial rating

Latest rating


Credit Suisse


Outperform the market



RBC Capital Mkts

Initial Comment

Consistent with the plate

Notify of
Inline Feedbacks
View all Intels

The world’s largest automobile group company: General Motors Company (GM) (1897)

Drug Development Company: SCYNEXIS, Inc. (SCYX)